Literature DB >> 10981100

Antihypertensive therapy and progression of chronic renal disease.

L D Dworkin1, D G Shemin.   

Abstract

This paper reviews findings on the relationship between blood pressure control and the progression of renal disease. Experimental studies demonstrate a correlation between systemic blood pressure and histologic glomerular injury and the delay in progression of renal disease with antihypertensive therapy, particularly with angiotensin-converting enzyme inhibitors. Recent clinical findings are reviewed, including epidemiologic data linking hypertension to subsequent renal disease, and clinical studies showing a beneficial effect on progression of renal disease with lower than usual blood pressure targets.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10981100     DOI: 10.1007/s11906-999-0058-x

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  46 in total

1.  Angiotensin-converting enzyme inhibition in the prevention and treatment of chronic renal damage in the hypertensive fawn-hooded rat.

Authors:  G H Verseput; A P Provoost; B B Braam; J J Weening; H A Koomans
Journal:  J Am Soc Nephrol       Date:  1997-02       Impact factor: 10.121

2.  Regulation of extracellular matrix by mechanical stress in rat glomerular mesangial cells.

Authors:  T Yasuda; S Kondo; T Homma; R C Harris
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

3.  Increased glomerular capillary pressure and size mediate glomerulosclerosis in SHR juxtamedullary cortex.

Authors:  B M Iversen; K Amann; F I Kvam; X Wang; J Ofstad
Journal:  Am J Physiol       Date:  1998-02

Review 4.  Sodium balance in renal failure.

Authors:  D Shemin; L D Dworkin
Journal:  Curr Opin Nephrol Hypertens       Date:  1997-03       Impact factor: 2.894

5.  Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

Authors: 
Journal:  Lancet       Date:  1997-06-28       Impact factor: 79.321

6.  Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italian Cooperative Study Group.

Authors:  F Locatelli; D Marcelli; M Comelli; D Alberti; G Graziani; G Buccianti; B Redaelli; A Giangrande
Journal:  Nephrol Dial Transplant       Date:  1996-03       Impact factor: 5.992

7.  Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension.

Authors:  B Hocher; C Thöne-Reineke; P Rohmeiss; F Schmager; T Slowinski; V Burst; F Siegmund; T Quertermous; C Bauer; H H Neumayer; W D Schleuning; F Theuring
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

8.  "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis.

Authors:  R D Toto; H C Mitchell; R D Smith; H C Lee; D McIntire; W A Pettinger
Journal:  Kidney Int       Date:  1995-09       Impact factor: 10.612

9.  Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney.

Authors:  A Benigni; C Zola; D Corna; S Orisio; D Facchinetti; L Benati; G Remuzzi
Journal:  Am J Kidney Dis       Date:  1996-03       Impact factor: 8.860

10.  The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.

Authors:  S Klahr; A S Levey; G J Beck; A W Caggiula; L Hunsicker; J W Kusek; G Striker
Journal:  N Engl J Med       Date:  1994-03-31       Impact factor: 91.245

View more
  1 in total

Review 1.  Systemic hypertension and proteinuria in childhood chronic renal parenchymal disease: role of antihypertensive drug management.

Authors:  Giacomo D Simonetti; Laura Santoro; Alessandra Ferrarini; Laura Crosazzo-Franscini; Emilio Fossali; Mario G Bianchetti
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.